← Back to Search

Chemotherapy

Bevacizumab for Cervical Cancer

Phase 2

Waitlist Available

Led By Marilyn Huang, MD, MS

Research Sponsored by University of Miami

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients must have histologically confirmed recurrent, persistent or metastatic (primary stage IVB) squamous cell carcinoma, adenosquamous carcinoma or adenocarcinoma of the cervix that is not amenable to curative treatment with surgery and/or radiation therapy.

All patients must have measurable disease as defined by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1.

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 24 months

Awards & highlights

Study Summary

This trial will test whether combining two chemotherapy drugs with bevacizumab and pembrolizumab is more effective in treating cervical cancer than the standard chemotherapy regimen.

Eligible Conditions

Cervical Cancer

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 24 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 24 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Objective Response Rate (ORR)

Secondary outcome measures

Overall Survival (OS)

Progression-Free Survival (PFS)

Therapeutic procedure

Trial Design

1Treatment groups

Experimental Treatment

Group I: Pembrolizumab, Chemotherapy, BevacizumabExperimental Treatment5 Interventions

On day 1 of each 21 day cycle, participants will be administered Pembrolizumab 200mg (IV); Chemotherapy including Paclitaxel 175mg/m2 or 135 mg/m2 (IV), and Cisplatin 50mg/m2 (IV) or Carboplatin AUC 5; and Bevacizumab 15mg/kg (IV).

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Bevacizumab

2013

Completed Phase 4

~5280

Carboplatin

2014

Completed Phase 3

~6670

Pembrolizumab

2017

Completed Phase 2

~2010

Paclitaxel

2011

Completed Phase 4

~5380

Cisplatin

2013

Completed Phase 3

~1940

0 / 10Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of MiamiLead Sponsor

899 Previous Clinical Trials

409,715 Total Patients Enrolled

Merck Sharp & Dohme LLCIndustry Sponsor

3,886 Previous Clinical Trials

5,054,536 Total Patients Enrolled

Marilyn Huang, MD, MSPrincipal Investigator - University of Miami

Univ of Miami Hosp & Clinics-Sylvester Comp Cancer Center, University of Miami Hospital

Eastern Va Medical School Of The Medical College Of Hampton Road (Medical School)

Ny And Presby Hospital (Residency)

2 Previous Clinical Trials

26 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What health conditions are most often addressed with Pembrolizumab?

"Pembrolizumab is indicated to treat various maladies and can be used in cases of Hodgkin Disease, Squamous cell carcinoma, and Melanoma."

Answered by AI

How much risk do patients face when using Pembrolizumab?

"The safety of Pembrolizumab is estimated to be a 2 on our scale, as this Phase 2 trial has data indicating it is safe but not yet proven effective."

Answered by AI

Are there any open slots for participants in this trial?

"According to the information on clinicaltrials.gov, this trial is presently looking for volunteers and has been since its first posting on September 6th 2018. The details were most recently updated October 1st 2022."

Answered by AI

How many individuals have taken part in this clinical research?

"Correct, according to clinicaltrials.gov this medical trial is currently recruiting patients. It was initially announced on September 6th 2018 and was last updated October 1st 2022. 40 participants must be sourced from a single location in order for the study to continue."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer

Marilyn Huang, MD, MS 2018. "Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03367871.